VAGIFEM's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5860946 | NOVO NORDISK INC | Instrument for inserting a suppository |
Jul, 2017
(6 years ago) | |
| US7018992 | NOVO NORDISK INC | Hormone composition |
Sep, 2022
(1 year, 7 months ago) | |
Vagifem is owned by Novo Nordisk Inc.
Vagifem contains Estradiol.
Vagifem has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Vagifem are:
- US5860946
- US7018992
Vagifem was authorised for market use on 25 November, 2009.
Vagifem is available in tablet;vaginal dosage forms.
Vagifem can be used as treatment of atrophic vaginitis due to menopause.
The generics of Vagifem are possible to be released after 17 September, 2022.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-122) | Nov 25, 2012 |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 25 November, 2009
Treatment: Treatment of atrophic vaginitis due to menopause
Dosage: TABLET;VAGINAL
How can I launch a generic of VAGIFEM before it's drug patent expiration?
More Information on Dosage
VAGIFEM family patents
